simvastatin has been researched along with Insulin Resistance in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (33.33) | 29.6817 |
| 2010's | 33 (57.89) | 24.3611 |
| 2020's | 5 (8.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Li, P; Liu, H; Meng, L; Wang, K; Wang, L; Yang, H; Zheng, Z; Zhu, L | 2 |
| da Rocha, IG; da Silva Júnior, JG; da Silva Neto, JC; de Araújo, HDA; de Menezes Lima, VL; de Oliveira Assis, SP; Oliveira, RN | 1 |
| Malakul, W; Phetrungnapha, A; Termkwancharoen, C; Tunsophon, S | 1 |
| Bangeppagari, M; Bellamkonda, R; Bhadramraju, R; Desireddy, S; Devarakonda, VLNP; Gujjala, S; Kameswaran, S; Ramaswamy, R | 1 |
| Almeida, OR; Campos-Staffico, AM; Carvalho, LSF; Cintra, RMR; Moura, FA; Nadruz, W; Quinaglia E Silva, JC; Sposito, AC | 1 |
| Dela, F; Dohlmann, TL; Hansen, M; Helge, JW; Kelly, B; Kuhlman, AB; Morville, T | 1 |
| Dandanell, S; Dela, F; Helge, JW; Larsen, S; Prats, C; Vigelsø, A | 1 |
| Byun, MR; Hong, JH; Hwang, ES; Hwang, JH; Il Park, J; Jeong, H; Kim, AR; Kim, HK; Kim, KM; Moon, SA; Oh, HT; Yaffe, MB | 1 |
| Bouitbir, J; Krähenbühl, S; Panajatovic, MV; Sanvee, GM | 1 |
| Ganesan, S; Ito, MK | 1 |
| Huang, Y; Jin, J; Kirkwood, KL; Li, Y; Lopes-Virella, MF; Lu, Z; Machado, ER; Yu, H; Zhang, X | 1 |
| Krysiak, R; Okopien, B; Zmuda, W | 3 |
| Hu, S; Huang, X; Ma, X; Pang, S; Wang, L; Wang, S | 1 |
| Bosco, AA; Eleuterio, N; Petreanu, M; Sandrim, VC | 1 |
| Constantin-Teodosiu, D; Greenhaff, PL; Mallinson, JE; Marimuthu, K; Murton, A; Rennie, MJ; Selby, A; Smith, K | 1 |
| Bekmukhambetov, Y; Dworacka, M; Dworacki, G; Iskakova, S; Zharmakhanova, G | 1 |
| Han, SH; Hayashi, T; Kim, EY; Koh, KK; Lee, Y; Oh, PC; Park, YM; Sakuma, I; Shin, EK | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Kain, V; Kapadia, B; Misra, P; Saxena, U | 1 |
| Kokkola, T; Modi, S; Yaluri, N | 1 |
| Han, SH; Kim, SJ; Koh, KK; Lee, Y; Park, JB; Quon, MJ; Shin, EK | 1 |
| Forst, T; Hanefeld, M; Kann, PH; Karagiannis, E; Lübben, G; Pfützner, A; Schöndorf, T; Wilhelm, B | 1 |
| Baker, WL; Coleman, CI; Talati, R; White, CM | 1 |
| Bellia, A; Cardillo, C; Donadel, G; Fabiano, R; Galli, A; Lauro, D; Lombardo, MF; Rizza, S; Sbraccia, P; Tesauro, M | 1 |
| Asadi, N; Dehbashi, S; Ghaffarpasand, F; Kazerooni, T; Kazerooni, Y; Shojaei-Baghini, A | 1 |
| Cengiz, SD; Dünder, I; Kaya, C; Pabuccu, R | 1 |
| Batista, MC; Ferreira, SR; Kater, AL | 1 |
| Bonab, AA; Carter, EA; Fischman, AJ; Kaneki, M; Paul, K; Tompkins, RG; Yu, YM | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Elisaf, M; Kei, AA; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H; Moutzouri, E | 1 |
| Bernardes, N; Brito, Jde O; De Angelis, K; Irigoyen, MC; Sanches, IC; Silva, RJ | 1 |
| Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A | 1 |
| Andreadi, K; Bellia, A; Cardillo, C; Donadel, G; Fabiano, R; Federici, M; Lauro, D; Lombardo, MF; Quon, MJ; Rizza, S; Sbraccia, P; Tesauro, M | 1 |
| Bao, MC; Bu, PL; Chen, YG; Gao, HQ; Ji, XP; Li, CB; Li, XX; Zhang, J; Zhang, Y | 1 |
| Krysiak, R; Okopien, B | 1 |
| Bang, LE; Bundgaard, H; Dela, F; Hansen, CN; Helge, JW; Hey-Mogensen, M; Larsen, S; Nielsen, LB; Stride, N | 1 |
| Borthwick, F; Cheeseman, CI; Hassanali, Z; Mangat, R; Proctor, SD; Russell, JC; Uwiera, RR; Vine, DF; Warnakula, S | 1 |
| Faust, M | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Ahn, JY; Ahn, TH; Choi, IS; Chung, WJ; Han, SH; Kang, MH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK | 1 |
| Reasner, CA | 1 |
| Ahn, JY; Han, SH; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Quon, MJ; Shin, EK | 1 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Ahmed, MH; Osman, MM; Saad, RA | 1 |
| Nesto, RW; Singh, PP | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Baurecht, W; Forst, T; Hanefeld, M; Hohberg, C; Karagiannis, E; Koehler, C; Lübben, G; Marx, N; Pfützner, A; Weber, M | 1 |
| Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A | 1 |
| Devaraj, S; Jialal, I; Siegel, D | 1 |
| Hu, WL; Li, JJ; Qian, SB; Qiao, SB | 1 |
| Ahn, JY; Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Quon, MJ; Shin, EK | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Bennani-Kabchi, N; Cherrah, Y; El Bouayadi, F; Fdhil, H; Kehel, L; Marquie, G | 1 |
| Castro Cabezas, M; de Jaegere, PP; Erkelens, DW; Halkes, CJ; Plokker, HW; van Der Helm, Y; van Dijk, H | 1 |
3 review(s) available for simvastatin and Insulin Resistance
| Article | Year |
|---|---|
Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Blood Glucose; Blood Pressure; Body Size; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Patient Selection; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2005 |
24 trial(s) available for simvastatin and Insulin Resistance
| Article | Year |
|---|---|
Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction.
Topics: Adult; Drug Administration Schedule; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Simvastatin; ST Elevation Myocardial Infarction; Young Adult | 2019 |
Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women: the LIFESTAT study.
Topics: Aged; Blood Glucose; C-Peptide; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Middle Aged; Simvastatin; Ubiquinone | 2019 |
The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Combined Modality Therapy; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hypercholesterolemia; Inflammation Mediators; Insulin Resistance; Lipids; Male; Middle Aged; Risk Reduction Behavior; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Effect of simvastatin treatment on plasma visfatin levels in obese women.
Topics: Adult; Body Mass Index; Cholesterol; Cytokines; Female; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Simvastatin; Triglycerides | 2014 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients.
Topics: Adiponectin; C-Reactive Protein; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Leptin; Lipoproteins; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Vasodilation | 2009 |
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
Topics: Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus; Double-Blind Method; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Reference Values; Retinol-Binding Proteins, Plasma; Simvastatin; Thiazolidinediones | 2009 |
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Blood Glucose; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Necrosis Factor-alpha; Vasodilation | 2010 |
Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Metformin; Placebos; Polycystic Ovary Syndrome; Simvastatin; Testosterone; Young Adult | 2010 |
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Inflammation; Insulin; Insulin Resistance; Luteinizing Hormone; Oxidative Stress; Polycystic Ovary Syndrome; Prospective Studies; Pyrroles; Simvastatin; Testosterone; Young Adult | 2010 |
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
Topics: Adolescent; Adult; Aged; Anthropometry; Anticholesteremic Agents; Azetidines; Biomarkers; Blood Coagulation; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Middle Aged; Prediabetic State; Simvastatin; Young Adult | 2010 |
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.
Topics: Aged; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fasting; Female; Fluorobenzenes; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Medication Adherence; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Glucose Clamp Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation Mediators; Insulin Resistance; Lipids; Losartan; Male; Middle Aged; Simvastatin; Ultrasonography | 2012 |
Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy.
Topics: Adiponectin; Biomarkers; Blood Glucose; Brachial Artery; C-Reactive Protein; Chi-Square Distribution; Cross-Over Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Glucose Clamp Technique; Glycated Hemoglobin; Homeostasis; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Leptin; Lipids; Male; Middle Aged; Pyrimidines; Rome; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose.
Topics: Antigens; Blood Coagulation; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Factor VII; Fasting; Female; Fibrinogen; Fibrinolysis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Prediabetic State; Simvastatin | 2012 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Chemokine CCL2; Cross-Over Studies; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Losartan; Male; Malondialdehyde; Middle Aged; Simvastatin; Vasodilation | 2004 |
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Malondialdehyde; Ramipril; Simvastatin; Vasodilation | 2005 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
Topics: Adiponectin; Cardiovascular Diseases; Double-Blind Method; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Pioglitazone; Proinsulin; Prospective Studies; Risk Factors; Simvastatin; Thiazolidinediones | 2007 |
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Female; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Male; Metabolic Syndrome; Metformin; Middle Aged; Simvastatin | 2007 |
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
Topics: Adiponectin; Double-Blind Method; Homeostasis; Humans; Insulin Resistance; Metabolic Syndrome; Simvastatin | 2007 |
Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients.
Topics: Adiponectin; Apolipoproteins B; Blood Flow Velocity; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Placebos; Simvastatin; Vasodilation | 2008 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
30 other study(ies) available for simvastatin and Insulin Resistance
| Article | Year |
|---|---|
Mevalonate pathway orchestrates insulin signaling via RAB14 geranylgeranylation-mediated phosphorylation of AKT to regulate hepatic glucose metabolism.
Topics: Animals; Diterpenes; Glucose; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Liver; Male; Mechanistic Target of Rapamycin Complex 2; Mevalonic Acid; Mice; Mice, Inbred C57BL; Phosphorylation; Proto-Oncogene Proteins c-akt; rab GTP-Binding Proteins; Signal Transduction; Simvastatin; Transferases | 2022 |
Geranylgeranyl pyrophosphate depletion by statins compromises skeletal muscle insulin sensitivity.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Muscle, Skeletal; rab GTP-Binding Proteins; Simvastatin | 2022 |
Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance.
Topics: Animals; Carboxymethylcellulose Sodium; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Hormones; Hypolipidemic Agents; Insulin Resistance; Insulins; Lipoproteins, VLDL; Mice; Obesity; Phthalimides; Simvastatin; Transaminases; Triglycerides; Uric Acid | 2022 |
Naringin Ameliorates Skeletal Muscle Atrophy and Improves Insulin Resistance in High-Fat-Diet-Induced Insulin Resistance in Obese Rats.
Topics: Animals; Antioxidants; Diet, High-Fat; Flavanones; Glucose; Glucose Transporter Type 4; Glycogen; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Muscle, Skeletal; Muscular Atrophy; Obesity; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin | 2022 |
Pleiotropic effects of Salacia reticulata and Simvastatin on oxidative stress and insulin resistance in a rat model.
Topics: Animals; Diet, High-Fat; Insulin; Insulin Resistance; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Salacia; Simvastatin | 2023 |
Simvastatin-Induced Insulin Resistance May Be Linked to Decreased Lipid Uptake and Lipid Synthesis in Human Skeletal Muscle: the LIFESTAT Study.
Topics: Adiponectin; Adult; Blood Glucose; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Leptin; Lipid Metabolism; Male; Middle Aged; Muscle, Skeletal; Simvastatin | 2018 |
TAZ couples Hippo/Wnt signalling and insulin sensitivity through Irs1 expression.
Topics: Acyltransferases; Animals; Blood Glucose; Cell Line; Gene Expression Profiling; Gene Expression Regulation; Glucose; Glucose Transporter Type 4; HEK293 Cells; Hippo Signaling Pathway; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Knockout; Muscle Cells; Muscle, Skeletal; Mutagenesis, Site-Directed; Myoblasts; Pharmaceutical Vehicles; Protein Serine-Threonine Kinases; Signal Transduction; Simvastatin; Transcription Factors; Up-Regulation; Wnt Signaling Pathway | 2019 |
Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle.
Topics: Animals; Cell Line; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscle Fibers, Skeletal; Muscle, Skeletal; Random Allocation; Simvastatin | 2019 |
Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anticholesteremic Agents; Azetidines; Diabetes Mellitus; Drug Interactions; Ezetimibe; Glucose Transporter Type 4; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Simvastatin; Ubiquinone | 2013 |
Simvastatin inhibits LPS-induced alveolar bone loss during metabolic syndrome.
Topics: Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Blood Glucose; Chemotaxis, Leukocyte; Cholesterol; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Interleukin-6; Leukocytes; Lipopolysaccharides; Metabolic Syndrome; Osteoclasts; Palmitic Acid; Periodontitis; RANK Ligand; Rats; Rats, Zucker; Simvastatin; Triglycerides; X-Ray Microtomography | 2014 |
Effect of simvastatin on the expression of farnesoid X receptor in diabetic animal models of altered glucose homeostasis.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Homeostasis; Insulin Resistance; Liver X Receptors; Male; Orphan Nuclear Receptors; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Sterol Regulatory Element Binding Protein 1 | 2014 |
The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Middle Aged; Polycystic Ovary Syndrome; Simvastatin; Testosterone | 2014 |
The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report.
Topics: Adipokines; Adiponectin; Adult; C-Reactive Protein; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Simvastatin; Time Factors | 2014 |
Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Humans; Insulin Resistance; Male; Muscle Contraction; Muscle Proteins; Muscle Strength; Muscle Weakness; Reaction Time; RNA, Messenger; Simvastatin | 2015 |
[Simvastatin's effect on insulin resistance in rats with diabetes mellitus].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Rats; Simvastatin | 2015 |
Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia.
Topics: Adiponectin; Aged; Animals; Anticholesteremic Agents; Blood Pressure; C-Reactive Protein; Drug Therapy, Combination; Ezetimibe; Fat Body; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Randomized Controlled Trials as Topic; Rats; Simvastatin; Single-Blind Method | 2015 |
Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism.
Topics: Cholesterol; Fatty Acids; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Mevalonic Acid; PPAR gamma; Signal Transduction; Simvastatin | 2015 |
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation.
Topics: Animals; Cell Line; Cholesterol; Glucose; Glucose Transporter Type 4; Glycogen; Glycogen Synthase Kinase 3 beta; Insulin; Insulin Resistance; Muscle Fibers, Skeletal; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Simvastatin | 2016 |
Effect of simvastatin on burn-induced alterations in tissue specific glucose metabolism: implications for burn associated insulin resistance.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Brain; Burns; Fluorodeoxyglucose F18; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Mice; Myocardium; Radiopharmaceuticals; Rats; Simvastatin; Tissue Distribution | 2010 |
Simvastatin-induced cardiac autonomic control improvement in fructose-fed female rats.
Topics: Animals; Autonomic Nervous System; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Disease Models, Animal; Fasting; Female; Fructose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metabolic Syndrome; Rats; Rats, Wistar; Simvastatin; Time Factors | 2011 |
Simvastatin exerts cardioprotective effects and inhibits the activity of Rho-associated protein kinase in rats with metabolic syndrome.
Topics: Animals; Cardiotonic Agents; Heart; Heart Diseases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Metabolic Syndrome; Mitochondrial Swelling; Myocardium; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Phosphatase 1; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; Simvastatin; Vacuoles | 2012 |
Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance.
Topics: Blood Glucose; Case-Control Studies; Cell Respiration; Electron Transport; Electron Transport Complex I; Electron Transport Complex II; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Oxidative Phosphorylation; Simvastatin; Ubiquinone | 2013 |
Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biglycan; Cholesterol; Ezetimibe; Insulin Resistance; Lipoproteins; Male; Metabolic Syndrome; Rats; Simvastatin | 2012 |
[Statin treatment in type 2 diabetes. Is it a must today?].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Life Style; Middle Aged; Placebos; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2003 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Dyslipidemias; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Humans; Insulin Resistance; Simvastatin | 2006 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cells, Cultured; Coronary Disease; Diterpenes; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mevalonic Acid; Monocytes; Polyisoprenyl Phosphates; Resistin; Risk Factors; Rodentia; Signal Transduction; Simvastatin; Time Factors; Up-Regulation | 2007 |
[Therapeutic effect of Olea europea var. oleaster leaves on carbohydrate and lipid metabolism in obese and prediabetic sand rats (Psammomys obesus)].
Topics: Animals; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus; Gerbillinae; Insulin Resistance; Obesity; Phytotherapy; Plant Leaves; Plants, Medicinal; Prediabetic State; Simvastatin | 2000 |
Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin.
Topics: Apolipoproteins B; Area Under Curve; Complement C3; Coronary Artery Disease; Fasting; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Postprandial Period; Simvastatin; Triglycerides | 2001 |